MiRus

GA - MariettaMedical Devices1 H-1B visas (FY2023)

Focus: MiRus is an early-stage medical device company focused on spine implants and transcatheter aortic valve replacement (TAVR) devices in the musculoskeletal space. Founded in 2021 and headquartered in Marietta, GA, the company is pre-commercial with minimal scale data available.

Musculoskeletal

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About MiRus

AI assessmentNot Hiring

No open roles listed right now. Follow MiRus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Siegel Transcatheter Aortic Valve

Aortic Stenosis Symptomatic

N/A

Clinical Trials (1)

NCT06680427Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

N/A

Help build intelligence for MiRus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded (2021) medtech company with dual focus on high-value markets: spine and cardiac intervention
Portfolio includes TAVR devices targeting symptomatic severe aortic stenosis, a large unmet clinical need with significant commercial potential
H1B sponsorship demonstrated (1 approval, 0 denials in 2023), indicating openness to global talent acquisition

Watch Out For

Zero active job openings at time of analysis suggests company is not actively hiring or is in stealth mode—difficult to assess near-term growth plans
Pre-revenue status with no disclosed funding, financials, or employee count creates uncertainty around cash runway, burn rate, and organizational stability
Only 2 clinical trials active with no Phase 1, 2, or 3 programs disclosed; pipeline maturity and timeline to commercialization are unclear

Generated by Claude from MiRus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TAVR Device

Symptomatic Severe Native Aortic Stenosis

N/A

Clinical Trials (1)

NCT07278310STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 2 clinical trials

Top TAs: Cardiovascular

H-1B (2023): 1 approval

Therapeutic Area Focus

Cardiovascular

2 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo